Aims: We aimed to assess the utility of validated metabolomic-based non-invasive tests to estimate the prevalence of liver disease in overweight/obese T2DM patients.

Materials and Methods: A total of 97 T2DM patients with HbA1c <7% and BMI >25 kg/m2 were recruited. Patients underwent routine lab, liver ultrasound and FibroScan. OWLiver® Care test and OWLiver® test were measured (two serum-based, BMI-dependent lipidomic tests that discriminate between normal liver and NAFLD, and between isolated steatosis and NASH, respectively).

Results: Based on results from ultrasound and FibroScan, patients were divided into four groups (Table). The prevalence of NAFLD and NASH was 86.4% and 31.1%, respectively. Severe fibrosis (F2-F4) was found in 22.9% and cirrhosis (F4) in 12.2%. OWLiver® Care test classified correctly 95% of patients with NAFLD (AUC 0.929). It showed high sensitivity (95%) and high accuracy (80%). OWLiver® test showed high consistency with the results of ultrasound and FibroScan, classifying correctly 90% of the samples of patients with NASH.

Conclusions: The prevalence of NAFLD and NASH is high in overweight/obese T2DM patients. OWLiver® Care test and OWLiver® test can be good tools for early detection of NAFLD and NASH, respectively, in routine clinical practice.


V. Bellido: None. I. Martínez-Arranz: Employee; Self; OWL Metabolomics. I. Goicolea: None. A. Amor: None. J. Pi: None. A. Pérez: None. J. Espiga: Consultant; Self; Novo Nordisk A/S. C. Montalban: None. R. Mayo: Employee; Self; OWL Metabolomics. S. Gaztambide: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at